Comparative Volumetric Analyses Following Bevacizumab Therapy for a Patient With Concomitant Glioblastoma, Meningioma, and Dural Arteriovenous Fistula: A Case Report and Review of Literature.

Given that glioblastoma (GBM), meningioma (Mg), and dural arteriovenous fistula (dAVF) represent angiogenic diseases mainly caused by vascular endothelial growth factor (VEGF), bevacizumab (Bev) is expected to be effective against these diseases. We report a patient with concomitant GBM, Mg, and dAVF who was treated with neoadjuvant Bev, resulting in a reduction in the volume of GBM along with an improvement of clinical symptoms. An 85-year-old male presented with aphasia, gait disturbance, and dementia. Magnetic resonance imaging (MRI) showed a ring-enhanced intra-axial tumor with perifocal edema in the left temporal lobe, a dura-attached extra-axial tumor at the left sphenoid ridge, and dAVF at the left transverse-sigmoid sinus. Due to the age of the patient and low Karnofsky Performance Status (KPS) score, pharmacotherapy with a single dose of Bev was chosen over surgical resection. Three days after the Bev administration, aphasia and gait disturbance had dramatically improved. Volume reduction rates at one and five months after three administrations of Bev were 0.34% and 95.9% for GBM and 13.7% and 6.8% for meningioma, respectively. No significant change in dAVF was seen on digital subtraction angiography (DSA) during Bev therapy. VEGF concentration in GBM is known to be the highest among all types of brain tumors, including meningioma. VEGF might not play a pivotal role in the pathogenesis of dAVF. Based on this evidence from the present rare case with concomitant GBM, meningioma, and dAVF, responsiveness to Bev might depend on the level of VEGF expression.